Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Zoloft “Authorized” Generic Will Be Available From Ivax By Mid-2006

Executive Summary

Ivax will begin distributing an authorized generic version of Pfizer's Zoloft by mid-2006 under an agreement between the two companies
Advertisement

Related Content

Declaratory Judgment Ruling Will Add Uncertainty To Generic Launches
Zocor, Zoloft And Pravachol Will Be Key Generic Switches For Medco In ’06
Zoloft Patent Dispute: FTC Sides With Teva On Declaratory Judgment Rights
Paxil Generics Grab 65% Of New Scripts; Apotex May Sue Over Par/GSK Deal
Alpharma Generic Neurontin Approval Precedes FDA Reinspection
Apotex Generic Paxil Priced At 7% Discount Following “At Risk” Launch
Wellbutrin SR/Zyban Generics Will Not Be Blocked By Andrx Exclusivity
Forest Lexapro Strategy Changes: Reps Encouraging Switches From Celexa
Ivax Generic Zoloft Exclusivity Will Be Unaffected By New FDA Guidance
Ivax Generic Zoloft Exclusivity Will Be Unaffected By New FDA Guidance
Advertisement
UsernamePublicRestriction

Register

PS042249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel